Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- DOCS +17.1% (also authorizes new $70 mln share repurchase program), BLNK +13.8%, RPAY +11.7%, INDI +9.3%, SYNA +8.7%, NVTS +7.6%, VZIO +7.2%, ALRM +7.1%, ORGN +6.5%, ARLO +6.1%, AVPT +3.9%, RXST +2.9%, VRRM +2.5% (also authorizes new $100 mln share repurchase program), TSM +2.4%, SOUN +2.3%, LGF.A +2.2%, HOLX +2.2%, ONL +1.6%, EC +1.3%, LNW +1.1%
Other news:
- FIGS +10.8% (Ron Barron on CNBC says he is long FIGS)
- OUST +10.7% (announces major software achievements to serve lidar-powered smart infrastructure)
- IRWD +7% (files mixed shelf securities offering)
- TARS +4.9% (files $300 mln mixed shelf securities offering)
- VOR +4.3% (presents data on Trem-cel)
- EGRX +4.1% (to delay 10-Q filing)
- EVC +3.7% (CEO disclosed the purchase of 100000 shares at $3.85 (transaction date 11/8))
- AIZ +3% (authorizes additional $600 mln in share repurchases; increases dividend)
- HTGC +1.8% (receives SBA "green light" letter to submit its fourth SBIC license application)
- VCTR +1.3% (reports Oct AUM)
- PCRX +1.1% (FDA approval of expanded EXPAREL label to include two additional nerve block indications)
- APAM +1% (reports Oct AUM)
Analyst comments:
- VERA +8.1% (upgraded to Buy from Hold at Jefferies)
- XRAY +2.8% (upgraded to Outperform from Mkt Perform at William Blair)
- BJ +2.2% (upgraded to Buy from Hold at Gordon Haskett)
- HSIC +1.8% (upgraded to Buy from Hold at Stifel)
- TOST +1.3% (upgraded to Outperform from Neutral at Robert Baird)